EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial

Petr Ostadal iD, Richard Rokyta, Jiri Karasek, Andreas Kruger, Dagmar Vondrakova, Marek Janotka, Jan Naar iD, Jana Smalcova iD, Marketa Hubatova, Milan Hromadka, Stefan Volovar, Miroslava Seyfrydova und 5 weitere

Circulation · 07.02.2023 · 147 (6) · 454-464

DOI: 10.1161/circulationaha.122.062949 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 07.02.2023. Verfasst von Petr Ostadal und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic (P.O., A.K., D.V., M.J., J.N.). Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Heart Arrest. Die Arbeit wurde bisher 495-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Czech Health Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly being used for circulatory support in patients with cardiogenic shock, although the evidence supporting its use in this context remains insufficient. The ECMO-CS trial (Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock) aimed to compare immediate implementation of VA-ECMO versus an initially conservative therapy (allowing downstream use of VA-ECMO) in patients with rapidly deteriorating or severe cardiogenic shock.

Methods

This multicenter, randomized, investigator-initiated, academic clinical trial included patients with either rapidly deteriorating or severe cardiogenic shock. Patients were randomly assigned to immediate VA-ECMO or no immediate VA-ECMO. Other diagnostic and therapeutic procedures were performed as per current standards of care. In the early conservative group, VA-ECMO could be used downstream in case of worsening hemodynamic status. The primary end point was the composite of death from any cause, resuscitated circulatory arrest, and implementation of another mechanical circulatory support device at 30 days.

Results

A total of 122 patients were randomized; after excluding 5 patients because of the absence of informed consent, 117 subjects were included in the analysis, of whom 58 were randomized to immediate VA-ECMO and 59 to no immediate VA-ECMO. The composite primary end point occurred in 37 (63.8%) and 42 (71.2%) patients in the immediate VA-ECMO and the no early VA-ECMO groups, respectively (hazard ratio, 0.72 [95% CI, 0.46–1.12]; P =0.21). VA-ECMO was used in 23 (39%) of no early VA-ECMO patients. The 30-day incidence of resuscitated cardiac arrest (10.3.% versus 13.6%; risk difference, –3.2 [95% CI, –15.0 to 8.5]), all-cause mortality (50.0% versus 47.5%; risk difference, 2.5 [95% CI, –15.6 to 20.7]), serious adverse events (60.3% versus 61.0%; risk difference, –0.7 [95% CI, –18.4 to 17.0]), sepsis, pneumonia, stroke, leg ischemia, and bleeding was not statistically different between the immediate VA-ECMO and the no immediate VA-ECMO groups.

Conclusions

Immediate implementation of VA-ECMO in patients with rapidly deteriorating or severe cardiogenic shock did not improve clinical outcomes compared with an early conservative strategy that permitted downstream use of VA-ECMO in case of worsening hemodynamic status. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02301819.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Extracorporeal Membrane OxygenationHeart ArrestHumansShock, CardiogenicHemodynamicsHospital MortalityRetrospective Studies

Stichwörter der Autor:innen

clinical trialshock, cardiogenictherapy

Autor:innen und Institutionen

  • Department of Cardiology, Na Homolce Hospital, Prague, Czech Republic (P.O., A.K., D.V., M.J., J.N.).
  • Department of Cardiology, University Hospital and Faculty of Medicine Pilsen, Charles University, Pilsen, Czech Republic (R.R., M. Hromadka, S.V., M. Seyfrydova).
  • Hospital Liberec, Liberec, Czech Republic (J.K.).
  • 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Liberec, Czech Republic (J.K., J.S., M. Hubatova, A.L., J.B.).
  • Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic (J.J., M. Svoboda).
  • Institute of Biostatistics and Analyses, Ltd, Brno, Czech Republic (M. Svoboda).

ORCID-Profile: Petr Ostadal, Jan Naar, Jana Smalcova

Förderung

  • Czech Health Research Council

Zitieren

APA

Ostadal, P., Rokyta, R., Karasek, J., Kruger, A., Vondrakova, D., Janotka, M., Naar, J., Smalcova, J., Hubatova, M., Hromadka, M., Volovar, S., Seyfrydova, M., Jarkovsky, J., Svoboda, M., Linhart, A., Belohlavek, J., & ECMO-CS Investigators (2023). Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. Circulation, 147(6), 454-464. https://doi.org/10.1161/circulationaha.122.062949

Vancouver

Ostadal P, Rokyta R, Karasek J, Kruger A, Vondrakova D, Janotka M, et al. Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial. Circulation. 2023;147(6):454-464. doi:10.1161/circulationaha.122.062949

BibTeX
@article{Ostadal2023,
  author = {Ostadal, Petr and Rokyta, Richard and Karasek, Jiri and Kruger, Andreas and Vondrakova, Dagmar and Janotka, Marek and Naar, Jan and Smalcova, Jana and Hubatova, Marketa and Hromadka, Milan and Volovar, Stefan and Seyfrydova, Miroslava and Jarkovsky, Jiri and Svoboda, Michal and Linhart, Ales and Belohlavek, Jan and ECMO-CS Investigators, ECMO-CS Investigators},
  title = {Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial},
  journal = {Circulation},
  year = {2023},
  volume = {147},
  number = {6},
  pages = {454--464},
  doi = {10.1161/circulationaha.122.062949}
}
Kostenlos starten →